RT Journal Article
SR Electronic
T1 Genotyping and population structure of the China Kadoorie Biobank
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.05.02.22274487
DO 10.1101/2022.05.02.22274487
A1 Robin G Walters
A1 Iona Y Millwood
A1 Kuang Lin
A1 Dan Schmidt Valle
A1 Pandora McDonnell
A1 Alex Hacker
A1 Daniel Avery
A1 Na Cai
A1 Warren W Kretzschmar
A1 M Azim Ansari
A1 Paul A Lyons
A1 Rory Collins
A1 Peter Donnelly
A1 Michael Hill
A1 Richard Peto
A1 Hongbing Shen
A1 Xin Jin
A1 Chao Nie
A1 Xun Xu
A1 Yu Guo
A1 Canqing Yu
A1 Jun Lv
A1 Robert J Clarke
A1 Liming Li
A1 Zhengming Chen
A1 the China Kadoorie Biobank Collaborative Group
YR 2022
UL http://medrxiv.org/content/early/2022/05/03/2022.05.02.22274487.abstract
AB China Kadoorie Biobank is a population-based prospective cohort of >512,000 adults recruited in 2004-2008 from 10 geographically diverse regions across China. Detailed data from questionnaire and physical measurements were collected at baseline, with additional measurements at three resurveys involving approximately 5% of surviving participants. Incident disease events are captured through electronic linkage to death and disease registries and to the national health insurance system. Genome-wide genotyping has been conducted for >100,000 participants using custom-designed Axiom® arrays. Analysis of these data reveals extensive relatedness within the CKB cohort, signatures of recent consanguinity, and principal component signatures reflecting large-scale population movements from recent Chinese history. In addition to numerous CKB studies of candidate drug targets and disease risk factors, CKB has made substantial contributions to many international genetics consortia. Collected biosamples are now being used for high-throughput ‘omics assays which, together with planned whole genome sequencing, will continue to enhance the scientific value of this biobank.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe CKB baseline survey and the first re-survey were supported by the Kadoorie Charitable Foundation in Hong Kong. Long-term follow-up was supported by the Wellcome Trust (212946/Z/18/Z, 202922/Z/16/Z, 104085/Z/14/Z, 088158/Z/09/Z), the National Key Research and Development Program of China (2016YFC0900500, 2016YFC0900501, 2016YFC0900504, 2016YFC1303904), and the National Natural Science Foundation of China (91843302). DNA extraction and genotyping was funded by GlaxoSmithKline, and the UK Medical Research Council (MC-PC-13049, MC-PC-14135). The project is supported by core funding from the UK Medical Research Council (MC_UU_00017/1, MC_UU_12026/2, MC_U137686851), Cancer Research UK (C16077/A29186; C500/A16896), and the British Heart Foundation (CH/1996001/9454) to the Clinical Trial Service Unit and Epidemiological Studies Unit and to the MRC Population Health Research Unit at Oxford University.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Oxford Tropical Research Ethics Committee of University of Oxford gave ethical approval for this work. Ethical Review Committees of the Chinese Centre for Disease Control and Prevention, Chinese Academy of Medical Sciences gave ethical approval for this work. Institutional Review Board (IRB) at Peking University gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData from baseline, first and second resurveys, and disease follow-up are available under the CKB Open Access Data Policy to bona fide researchers. Sharing of genotyping data is currently constrained by the Administrative Regulations on Human Genetic Resources of the People's Republic of China. Access to these and certain other data is available through collaboration with CKB researchers. Full details of the CKB Data Sharing Policy are available at www.ckbiobank.org.